A Likelihood Perspective on Dose-Finding Study Designs in Oncology
Zhiwei Zhang

TL;DR
This paper introduces a likelihood-based framework using generalized likelihood ratios (GLRs) for dose-finding in oncology, providing a unified, interpretable approach to decision-making that improves over existing interval designs.
Contribution
It develops a GLR-based interval design for dose escalation decisions, offering a unified framework and comparisons with existing methods, including extensions to nonparametric and parametric models.
Findings
GLR-based design offers a likelihood interpretation of interval designs.
Comparison reveals differences and potential improvements over existing designs.
Simulation shows isotonic GLR performs similarly to single-dose GLR, with advantages when models are correct.
Abstract
Dose-finding studies in oncology often include an up-and-down dose transition rule that assigns a dose to each cohort of patients based on accumulating data on dose-limiting toxicity (DLT) events. In making a dose transition decision, a key scientific question is whether the true DLT rate of the current dose exceeds the target DLT rate, and the statistical question is how to evaluate the statistical evidence in the available DLT data with respect to that scientific question. This article introduces generalized likelihood ratios (GLRs) that can be used to measure statistical evidence and support dose transition decisions. Applying this approach to a single-dose likelihood leads to a GLR-based interval design with three parameters: the target DLT rate and two GLR cut-points representing the levels of evidence required for dose escalation and de-escalation. This design gives a likelihood…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsStatistical Methods in Clinical Trials · Optimal Experimental Design Methods · Health Systems, Economic Evaluations, Quality of Life
